Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$35.52M+93.07%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas Lingelbach
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 674
- Beta
- 1.35
- Country
- FR
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.96
Financials
Revenue
$35.52M+93.1%Net Income
$-31.72MEBITDA
$-22.91MFree Cash Flow
$-18.81M-659.5%EPS (diluted)
$-0.34Shares Outstanding (diluted)
94.82M+143.6%Operating Expenses
$29.04MCash & Debt
$121.48MReturn of Capital
$0.00Revenue by Segment (annual)
$149.57MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $174.66M | $-115.19M | $-1.32 |
| 2024 | $169.58M | $-12.25M | $-0.17 |
| 2023 | $153.71M | $-101.43M | $-1.46 |
| 2022 | $361.30M | $-143.28M | $-2.48 |
| 2021 | $348.08M | $-73.42M | $-1.50 |
| 2020 | $110.32M | $-64.39M | $-1.42 |
| 2019 | $126.20M | $-1.74M | $-0.04 |
| 2018 | $113.03M | $3.26M | $0.08 |
| 2017 | $105.29M | $-11.48M | $-0.30 |
| 2016 | $94.06M | $-49.18M | $-1.32 |
| 2015 | $78.36M | $-20.62M | $-0.56 |
| 2014 | $36.92M | $-26.27M | $-0.94 |
| 2013 | $30.45M | $-24.11M | $-1.22 |
| 2012 | $3.43M | $-14.84M | $-1.40 |
Valuation
VALNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-66.29%Social Signal Score
Mentions (4)
- Newsdefenseworld.net·12d ago·Neutral
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN) Valneva (NASDAQ: VALN - Get Free Report) and Septerna (NASDAQ: SEPN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability. Insider and Institutional Ownership 11.4% of Valneva shares are
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Valneva SE (VALN) Q2 2026 Earnings Call Transcript Valneva SE (VALN) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Negative
Valneva Q2 Earnings Call Highlights Valneva NASDAQ: VALN reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year ended June 30, 2026, provided key corporate updates, and reaffirmed its financial guidance for 2026. The half year financial report, including the condensed consolidated interim financial report and the half year manage…
View source ↗
Earnings
Thu, Nov 19(in 6 weeks)
Consensus estimate $-0.17 per share
Typical surprise -100.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.40 vs $-0.28miss
- Wed, May 13$-0.42 vs $-0.21miss
- Mon, Mar 16$-0.68 vs $-0.17miss
- Thu, Nov 20$-0.61 vs $-0.30miss
- Tue, Aug 12$-0.16 vs $-0.27beat
- Wed, May 7$-0.13 vs $-0.31beat
Estimates and results for VALN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in VALN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.